ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

RENE Reneuron Group Plc

3.05
0.00 (0.00%)
Last Updated: 00:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group Plc LSE:RENE London Ordinary Share GB00BF5G6K95 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3.05 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

ReNeuron Group plc Update on Administration Process

08/05/2024 7:00am

RNS Regulatory News


RNS Number : 4659N
ReNeuron Group plc
08 May 2024
 

8 May 2024

 

ReNeuron Group plc

("ReNeuron", the "Group" or the "Company")

 

Update on Administration Process

 

ReNeuron Group plc (in administration) (AIM: RENE), a UK based leader in stem cell derived exosome technologies, provides an update on its ongoing administration which commenced on 20 March 2024.

 

Since the commencement of administration process, the Joint Administrators, alongside the Board of the Company, have been assessing a number of possible options, including the possible recapitalisation of the business by way of an equity fundraise, as well as the potential sale of the operating subsidiary of the Group or its assets on a piecemeal basis.

 

The Board has prepared a revised business plan which would enable the Group to continue to progress the development of its exosome platform on a lower cost base should it be able to secure an equity fundraise. As part of this, and in order to preserve value for creditors, the Joint Administrators are undertaking a cost rationalisation which has included, inter alia, the redundancy of several of the Group's employees as well as other cost cutting measures. Certain members of key Senior Management, including Iain Ross (Executive Chairman) and Randolph Corteling (Chief Scientific Officer) have remained with the business and continue to support the administrators.

 

A further update on the Administration Process will be made when appropriate.

 

Enquiries:

 

Cork Gully LLP

+44 (0)20 7268 2150 or

Stephen Cork, Joint Administrator

reneuron@corkgully.com

Mark Smith, Joint Administrator


 


ReNeuron

www.reneuron.com/investors

Iain Ross, Executive Chairman

Via Walbrook PR





Allenby Capital Limited (Nominated Adviser and Broker)

+44 (0)20 3328 5656

James Reeve/George Payne/ Dan Dearden-Williams (Corporate Finance)


Stefano Aquilino/Kelly Gardiner (Sales & Corporate Broking)




Walbrook PR (Media & Investor Relations)

+44 (0)20 7933 8780 or reneuron@walbrookpr.com

Paul McManus / Alice Woodings

+44 (0)7980 541 893 / +44 (0)7407 804 654

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDUBOURSRUVRAR

1 Year Reneuron Chart

1 Year Reneuron Chart

1 Month Reneuron Chart

1 Month Reneuron Chart

Your Recent History

Delayed Upgrade Clock